Accès à distance ? S'identifier sur le proxy UCLouvain
Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment
Primary tabs
- Open access
- 121.54 K
| Document type | Communication à un colloque (Conference Paper) – Abstract, Présentation orale avec comité de sélection |
|---|---|
| Access type | Accès libre |
| Publication date | 2008 |
| Language | Anglais |
| Conference | "European society for medical oncology", Stockholm (du 12/09/2008 au 16/09/2008) |
| Journal information | "Annals of Oncology" - Vol. 19, no. Sppl. 8, p. VIII61-VIII62 (2008) |
| Peer reviewed | yes |
| issn | 0923-7534 |
| e-issn | 1569-8041 |
| Publisher | Oxford University Press ((United Kingdom) Oxford) |
| Affiliations |
GlaxoSmithKline Biologicals
- cancer immunotherapeuthics Université de Nantes - Unit of Skin Cancer UCL - FSA/INGI - Département d'ingénierie informatique Institut Gustav Roussy - Academic unit of clinical ecology Erasmus university medical center - Medical oncology |
| Keywords | 3349 |
| Links |
| Bibliographic reference | Louahed, Jamila ; Dréno, B. ; Gaulis, Swann ; Helleputte, Thibault ; Dupont, Pierre ; et. al. Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment.European society for medical oncology (Stockholm, du 12/09/2008 au 16/09/2008). In: Annals of Oncology, Vol. 19, no. Sppl. 8, p. VIII61-VIII62 (2008) |
|---|---|
| Permanent URL | http://hdl.handle.net/2078.1/107830 |